BPGbio, University of Oxford team up on treatments for Parkinson’s

The Centre for Medicines Discovery at the University of Oxford and AI-focused biopharmaceutical company BPGbio have launched a five-year collaboration to develop new treatments for brain diseases like Parkinson’s. Their goal is to use BPGbio’s NAi interrogative biology platform, which combines patient biology with AI analysis, to accelerate biomarker discovery and therapeutic development. The partnership will focus on targeted protein degradation, particularly the elimination of harmful proteins like alpha-synuclein, which plays a key role in Parkinson’s disease. This approach aims to slow disease progression and create new therapies for previously untreatable conditions. The collaboration combines BPGbio's protein degradation technology with Oxford’s research expertise to advance treatments for conditions with significant unmet needs, including Parkinson’s, cancers, and other central nervous system disorders.